Axa
DNLI icon

Axa’s Denali Therapeutics DNLI Stock Holding History

Axa’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-293,853
Closed -$4.11M – 352
2025
Q2 		$4.11M Buy
293,853
+472
+0.2% +$6.64K 0.01% 603
2025
Q1 		$3.99M Sell
293,381
-374
-0.1% -$7.17K 0.01% 599
2024
Q4 		$5.99M Sell
293,755
-51,128
-15% -$1.31M 0.02% 494
2024
Q3 		$10M Buy
344,883
+98
+0% +$2.43K 0.03% 393
2024
Q2 		$8.01M Sell
344,785
-16,023
-4% -$308K 0.02% 430
2024
Q1 		$7.4M Buy
360,808
+213
+0.1% +$4K 0.02% 469
2023
Q4 		$7.74M Buy
360,595
+6,066
+2% +$120K 0.03% 451
2023
Q3 		$7.31M Sell
354,529
-3,853
-1% -$97.7K 0.03% 452
2023
Q2 		$10.6M Buy
358,382
+69,140
+24% +$1.94M 0.04% 397
2023
Q1 		$6.66M Sell
289,242
-678
-0.2% -$18.7K 0.02% 492
2022
Q4 		$8.06M Buy
289,920
+41,148
+17% +$1.22M 0.03% 483
2022
Q3 		$7.63M Buy
248,772
+1,081
+0.4% +$35.1K 0.03% 487
2022
Q2 		$7.29M Buy
247,691
+47,123
+23% +$1.23M 0.03% 493
2022
Q1 		$6.45M Sell
200,568
-19,498
-9% -$671K 0.02% 579
2021
Q4 		$9.81M Buy
220,066
+18,486
+9% +$876K 0.03% 494
2021
Q3 		$10.2M Buy
201,580
+18,880
+10% +$1.06M 0.03% 492
2021
Q2 		$14.3M Buy
182,700
+5,722
+3% +$354K 0.04% 434
2021
Q1 		$10.1M Buy
176,978
+18,788
+12% +$1.26M 0.03% 513
2020
Q4 		$13.3M Sell
158,190
-64,881
-29% -$3.92M 0.04% 428
2020
Q3 		$7.99M Sell
223,071
-2,119
-0.9% -$63.8K 0.03% 522
2020
Q2 		$5.45M Buy
225,190
+37,228
+20% +$875K 0.02% 592
2020
Q1 		$3.29M Buy
+187,962
New +$3.92M 0.02% 629

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Axa's DNLI Position: Q3 2025 in Review

Axa sold out of Denali Therapeutics (DNLI) in Q3 2025, closing a stake of 293,853 shares — an estimated $4.11M sold.

Axa first reported a position in DNLI in Q1 2020 and held it in 22 quarters. The position peaked at $14.3M in Q2 2021. 240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

  • Axa reported no remaining Denali Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Axa sold 293,853 Denali Therapeutics shares in Q3 2025, an estimated $4.11M.
  • Axa first reported a position in Denali Therapeutics in Q1 2020 and held it in 22 quarters.
  • Axa's Denali Therapeutics position peaked at $14.3M in Q2 2021.
  • 240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.